What is Altimmune's stock-based comp?

Altimmune (ALT) reported stock-based comp of $3.38M in Q1 2026.

How has Altimmune's stock-based comp changed year-over-year?

Altimmune's stock-based comp decreased by 15.9% year-over-year, from $4.02M to $3.38M.

What is the long-term trend for Altimmune's stock-based comp?

Over 4 years (2021 to 2025), Altimmune's stock-based comp has grown at a 30.6% compound annual growth rate (CAGR), from $5.52M to $16.08M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Altimmune ALT Stock-Based Comp

Stock-Based Comp at other companies

Eli LillyLLY

$161M+4.5%

Merck & Co.MRK

$185M-5.1%

Madrigal Pharmaceuticals, Inc.MDGL

$34.02M+62.5%

Viking TherapeuticsVKTX

$10.34M-8.9%

Wave Life SciencesWVE

$9.06M+83.0%

MeiraGTx Holdings plcMGTX

$3.65M-25.2%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's stock-based comp?: Altimmune (ALT) reported stock-based comp of $3.38M in Q1 2026.
How has Altimmune's stock-based comp changed year-over-year?: Altimmune's stock-based comp decreased by 15.9% year-over-year, from $4.02M to $3.38M.
What is the long-term trend for Altimmune's stock-based comp?: Over 4 years (2021 to 2025), Altimmune's stock-based comp has grown at a 30.6% compound annual growth rate (CAGR), from $5.52M to $16.08M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.